ClinicalTrials.Veeva

Menu

Efficacy of Platelet-Rich Plasma Versus Mesotherapy in Androgenetic Alopecia: A Retrospective Study

F

Faculty Hospital Kralovske Vinohrady

Status

Completed

Conditions

Hair Loss
Alopecia
Androgenetic Alopecia

Treatments

Other: Mesotherapy
Other: Platelet-rich plasma

Study type

Observational

Funder types

Other

Identifiers

NCT05129800
NKS1002

Details and patient eligibility

About

This is a comparative retrospective study of the efficacy of platelet-rich plasma injections and injections with commercial products advertised to promote hair regrowth for patients with androgenetic alopecia.

Full description

Platelet-rich plasma (PRP) has been used for more than a decade in the treatment of androgenetic alopecia and hair loss. Platelets contain a range of growth factors , namely vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), epidermal growth factor (EGF) and transforming growth factor beta (TGF-beta) which stimulate and support hair growth. Several studies have been performed on patients with conflicting but generally positive results.

Mesotherapy is the technique of injecting a product into the dermis and subcutaneous tissue in order to rejuvenate the skin, induce lipolysis or promote hair growth. Various products exist with different formulations marketed to induce hair growth and sustain hair loss. Even though these products have been used for years, clinical evidence is lacking.

In this retrospective study, we will compare the efficacy of PRP and mesotherapy on hair growth based on the trichoscopic photos and phototrichographic analyses of our patients who underwent these procedures between 2011 and 2020.

Enrollment

72 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who underwent either PRP or mesotherapy at our dermatology clinic during 1/1/2011 and 30/12/2020
  • Male patients with a clinical/ trichoscopic/ histologic diagnosis of androgenetic alopecia (stage II to V according to the Hamilton-Norwood Scale)
  • Female patients with a clinical/ trichoscopic/ histologic diagnosis of androgenetic alopecia (stage I to III according to Ludwig Classification)
  • Patients receiving no treatment or being treated for more than six months for androgenetic alopecia without change in medication. Examples of medications and interventions include, oral/topical finasteride, oral/topical minoxidil, antiandrogens, hormonal substitution, hormonal contraceptives, phototherapy/laser, cryotherapy, microneedling.
  • Patients who underwent trichoscopic examination and phototrichographic evaluation with our digital dermatoscope, before treatment, a month after the last injection and 3 months after treatment.
  • Trichoscopic photos are required to be taken from the midfrontal area and from the vertex -defined as the intersection of the line through the midsagittal line and the line passing through the external auditory canals in the coronal plane.

Exclusion criteria

  • Patients with other types of alopecia, other than androgenetic alopecia
  • Patients with two or more diagnoses of hair loss , for example androgenetic alopecia and telogen effluvium or alopecia areata.
  • Patients who started concomitant medication for hair loss within six months of treatment with PRP or mesotherapy. Medications and interventions include, oral/topical finasteride, oral/topical minoxidil, antiandrogens, hormonal substitution, hormonal contraceptives, phototherapy/laser, cryotherapy, microneedling.
  • Hair transplantation to the vertex /midfrontal area
  • Patients with no trichoscopic examination/ phototrichographic evaluation
  • Patients lost to follow-up / withdrew from treatment

Trial design

72 participants in 4 patient groups

PRP 1
Description:
This is the group of patients who were injected with 5 ml of PRP prepared using a tube from a company 1
Treatment:
Other: Platelet-rich plasma
PRP 2
Description:
This is the group of patients who were injected with 5 ml of PRP prepared using a tube from a company 2
Treatment:
Other: Platelet-rich plasma
Mesotherapy 1
Description:
This is the group of patients who were injected with mesotherapy from a company 1
Treatment:
Other: Mesotherapy
Mesotherapy 2
Description:
This is the group of patients who were injected with mesotherapy from a company 2
Treatment:
Other: Mesotherapy

Trial contacts and locations

0

Loading...

Central trial contact

Athanasios J Stefanis; Athanasios J Stefanis, MUDr, MPharm

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems